Seth Richards
Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.
More From Seth Richards
Measuring Mylan’s Biggest Risks Moving Forward
Aside from the risky generic pharmaceutical industry, Mylan faces company-specific business risks like country risk, foreign exchange risk, and M&A risk.
Mylan’s Recent Acquisitions Continue to Strengthen Its Position in International Markets
Mylan takes an M&A strategy to save time related to compliance activities for obtaining regulatory approvals across various international markets.
Gauging Mylan’s Aggressive Acquisition Strategy
By acquiring UDL Laboratories, Mylan entered the unit dose and the long-term care market. In 1998, Mylan added Penederm to its dermatological division.
How Has Manufacturing Its Own Active Pharmaceutical Ingredients Helped Mylan?
Mylan is one of largest API (active pharmaceutical ingredient) manufacturers in the world, with nine API and intermediate manufacturing facilities.
Mylan Product Portfolio across Key Therapeutic Areas
Mylan is a leading pharmaceutical company that operates in more than 140 countries and operates across five different therapeutic areas.
Sizing up Mylan’s Blockbuster Drugs: Perforomist, Ultiva, and Emsam
Mylan NV is the generic drug leader in the US prescription drug market with blockbuster drugs such as Perforomist, Ultiva, and Emsam.
Assessing the Role of the EpiPen Auto-Injector in Mylan’s Revenues
Used to deliver Epinephrine in the treatment of severe allergic reactions, Mylan’s EpiPen auto-injectors hold the number one rank in the epinephrine market.
Mylan’s Business Model: A Key Investor Rundown
In 2014, Mylan earned about 85% of its total revenues from the US generic market, which is the largest generic market in the world.
Locating Mylan’s Geographic Market Strategy
Compared to peers Teva Pharmaceuticals, Valeant Pharmaceuticals, and Zoetis, Mylan earns substantially higher revenues from the US generic market.
Introducing Mylan, a Big International Gun in Generic Pharmaceuticals
Headquartered in the UK, Mylan is one of the biggest players in the generic pharmaceutical industry. It was founded by Milan Puskar and Don Panoj in 1961.
